Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder
Background: The difficulty in timely evaluating patient response to antidepressants has brought great challenge to the treatment of major depressive disorder (MDD). Some studies found that the electroencephalogram (EEG) microstates might be a reliable marker to evaluate patient response to treatment...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.695272/full |
id |
doaj-a308f1e67f0d4c1cb81862aea4dd89f2 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Danfeng Yan Danfeng Yan Danfeng Yan Jin Liu Jin Liu Mei Liao Mei Liao Bangshan Liu Bangshan Liu Shibin Wu Xueqin Li Xueqin Li Haolun Li Haolun Li Wenwen Ou Wenwen Ou Li Zhang Li Zhang Zexuan Li Zexuan Li Yan Zhang Yan Zhang Lingjiang Li Lingjiang Li |
spellingShingle |
Danfeng Yan Danfeng Yan Danfeng Yan Jin Liu Jin Liu Mei Liao Mei Liao Bangshan Liu Bangshan Liu Shibin Wu Xueqin Li Xueqin Li Haolun Li Haolun Li Wenwen Ou Wenwen Ou Li Zhang Li Zhang Zexuan Li Zexuan Li Yan Zhang Yan Zhang Lingjiang Li Lingjiang Li Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder Frontiers in Psychiatry major depressive disorders drug-naïve patient electroencephalogram EEG microstate first-episode depression |
author_facet |
Danfeng Yan Danfeng Yan Danfeng Yan Jin Liu Jin Liu Mei Liao Mei Liao Bangshan Liu Bangshan Liu Shibin Wu Xueqin Li Xueqin Li Haolun Li Haolun Li Wenwen Ou Wenwen Ou Li Zhang Li Zhang Zexuan Li Zexuan Li Yan Zhang Yan Zhang Lingjiang Li Lingjiang Li |
author_sort |
Danfeng Yan |
title |
Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder |
title_short |
Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder |
title_full |
Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder |
title_fullStr |
Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder |
title_full_unstemmed |
Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder |
title_sort |
prediction of clinical outcomes with eeg microstate in patients with major depressive disorder |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Psychiatry |
issn |
1664-0640 |
publishDate |
2021-08-01 |
description |
Background: The difficulty in timely evaluating patient response to antidepressants has brought great challenge to the treatment of major depressive disorder (MDD). Some studies found that the electroencephalogram (EEG) microstates might be a reliable marker to evaluate patient response to treatment. The present study aims to evaluate the relationship between EEG microstate parameters and MDD symptoms before and after treatment to identify predictive biological markers for patient response.Methods: Thirty drug-naïve MDD patients (20 females and 10 males) were enrolled in this study. All the patients received effective dosages of selective serotonin reuptake inhibitors, and EEG recordings were collected at baseline and 2 weeks of treatment. Brain activities during the eyes-closed state were recorded using 64-channel electroencephalography, and the patients' microstates were clustered into four maps according to their topography (labeled A, B, C, and D). The differences of EEG microstates before and after treatment were compared using paired t-test. Spearman correlation coefficients were calculated to identify the relationships between the improvement of depression and anxiety symptoms and microstate parameters.Results: The mean duration (69.67 ± 10.33 vs. 64.00 ± 7.70, p < 0.001) and occurrence (4.06 ± 0.69, vs. 3.69 ± 0.70, p = 0.002) of microstate B decreased significantly after treatment. The proportion of microstate B also decreased (27.53 ± 5.81, vs. 23.23 ± 4.61, p < 0.001), while the occurrence of microstate A increased after treatment. A significant negative correlation was found between the change of score of Hamilton Rating Scale for Anxiety and the increase of the occurrence of microstate A (r = −0.431, p < 0.05) after 2 weeks of treatment. The reduction of the duration of microstate B was found to be predictive of patient response to antidepressants after 3 months.Conclusion: This study explored the relationship between changes of EEG microstates and patient response to antidepressants. Depression symptoms might be associated with the duration of microstate B and anxiety symptoms related to the occurrence of microstate A. Therefore, the duration of microstate B and the occurrence of microstate A are potential biological markers for MDD patients' early response and further clinical outcomes. |
topic |
major depressive disorders drug-naïve patient electroencephalogram EEG microstate first-episode depression |
url |
https://www.frontiersin.org/articles/10.3389/fpsyt.2021.695272/full |
work_keys_str_mv |
AT danfengyan predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT danfengyan predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT danfengyan predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT jinliu predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT jinliu predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT meiliao predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT meiliao predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT bangshanliu predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT bangshanliu predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT shibinwu predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT xueqinli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT xueqinli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT haolunli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT haolunli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT wenwenou predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT wenwenou predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT lizhang predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT lizhang predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT zexuanli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT zexuanli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT yanzhang predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT yanzhang predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT lingjiangli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder AT lingjiangli predictionofclinicaloutcomeswitheegmicrostateinpatientswithmajordepressivedisorder |
_version_ |
1721205904834035712 |
spelling |
doaj-a308f1e67f0d4c1cb81862aea4dd89f22021-08-16T07:22:36ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402021-08-011210.3389/fpsyt.2021.695272695272Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive DisorderDanfeng Yan0Danfeng Yan1Danfeng Yan2Jin Liu3Jin Liu4Mei Liao5Mei Liao6Bangshan Liu7Bangshan Liu8Shibin Wu9Xueqin Li10Xueqin Li11Haolun Li12Haolun Li13Wenwen Ou14Wenwen Ou15Li Zhang16Li Zhang17Zexuan Li18Zexuan Li19Yan Zhang20Yan Zhang21Lingjiang Li22Lingjiang Li23National Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaShanxi Mental Health Center, Taiyuan, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaDepartment of Psychiatry, Nanning Fifth People's Hospital, Nanning, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaNational Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Psychiatry and Mental Health, Institute of Mental Health, Hunan Medical Center of Mental Health, China National Technology Institute on Mental Disorders, Changsha, ChinaBackground: The difficulty in timely evaluating patient response to antidepressants has brought great challenge to the treatment of major depressive disorder (MDD). Some studies found that the electroencephalogram (EEG) microstates might be a reliable marker to evaluate patient response to treatment. The present study aims to evaluate the relationship between EEG microstate parameters and MDD symptoms before and after treatment to identify predictive biological markers for patient response.Methods: Thirty drug-naïve MDD patients (20 females and 10 males) were enrolled in this study. All the patients received effective dosages of selective serotonin reuptake inhibitors, and EEG recordings were collected at baseline and 2 weeks of treatment. Brain activities during the eyes-closed state were recorded using 64-channel electroencephalography, and the patients' microstates were clustered into four maps according to their topography (labeled A, B, C, and D). The differences of EEG microstates before and after treatment were compared using paired t-test. Spearman correlation coefficients were calculated to identify the relationships between the improvement of depression and anxiety symptoms and microstate parameters.Results: The mean duration (69.67 ± 10.33 vs. 64.00 ± 7.70, p < 0.001) and occurrence (4.06 ± 0.69, vs. 3.69 ± 0.70, p = 0.002) of microstate B decreased significantly after treatment. The proportion of microstate B also decreased (27.53 ± 5.81, vs. 23.23 ± 4.61, p < 0.001), while the occurrence of microstate A increased after treatment. A significant negative correlation was found between the change of score of Hamilton Rating Scale for Anxiety and the increase of the occurrence of microstate A (r = −0.431, p < 0.05) after 2 weeks of treatment. The reduction of the duration of microstate B was found to be predictive of patient response to antidepressants after 3 months.Conclusion: This study explored the relationship between changes of EEG microstates and patient response to antidepressants. Depression symptoms might be associated with the duration of microstate B and anxiety symptoms related to the occurrence of microstate A. Therefore, the duration of microstate B and the occurrence of microstate A are potential biological markers for MDD patients' early response and further clinical outcomes.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.695272/fullmajor depressive disordersdrug-naïve patientelectroencephalogramEEG microstatefirst-episode depression |